Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks Therapeutics, which is being repped by Goodwin Procter.

U.S. President Donald Trump called Amazon Executive Chairman Jeff Bezos on Tuesday morning to complain about a report the ...

Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

Merck announced Monday it will acquire U.S. biotech company SpringWorks Therapeutics for $47 per share in cash, valuing the ...

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...